Aimed Monthly 

Join HealthyWomen on May 11, 2022, at 1PM-2PM ET for a virtual briefing on the provisions of the federal Cures 2.0 bill related to patient access, caregiver resources and supports, and telehealth. The panel of speakers will include representatives of the National Alliance for Caregiving, Oncology Nursing Society, and Aimed Alliance. Register for the briefing here.  

Recently, the White House released its 2022 National Drug Control Strategy, which proposed actions to curb substance use disorders and drug poisonings in the United States. The Strategy adopted a recommendation by ACTION for PDTs member, the Center for U.S. Policy, and recognized the role evidence-based digital therapies could play in helping treat substance use disorders. The Strategy recommended that federal and private health plans cover FDA-cleared and evidenced-based digital therapies, as well as health care providers’ costs in administering them. Read the 2022 National Drug Control Strategy here.  

The Food and Drug Administration published draft guidance on “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry.” The guidance provides recommendations to sponsors developing human drugs and medical devices on the approach for creating Race and Ethnicity Diversity Plans (Plans) to ensure enrollment in clinical trials of underrepresented racial and ethnic populations in the United States. The complete list of FDA recommendations for Plans can be found  here. 

Michigan joined a growing number of states that can now offer Medicaid and Children’s Health Insurance Program (CHIP) coverage for up to 12 months after a beneficiary gives birth. CMS estimates that nearly 16,000 pregnant and postpartum people in Michigan will be eligible for this expanded coverage, made possible through a new state plan opportunity created under the American Rescue Plan. Read more about Michigan’s Medicaid expansion here.